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SildenaﬁlPhosphodiesterase 5 (PDE5) inhibitors have recently been reported to exert beneﬁcial effects against ischemia–
reperfusion injury in several organs but their neuroprotective effects in brain stroke models are scarce. The
present studywas undertaken to assess the effects of sildenaﬁl against cell death caused by intrastriatal injection
ofmalonate, an inhibitor of succinate dehydrogenase; which produces both energy depletion and lesions similar
to those seen in cerebral ischemia. Our data demonstrate that sildenaﬁl (1.5 mg/kg by mouth (p.o.)), given
30 min before malonate (1.5 μmol/2 μL), signiﬁcantly decreased the lesion volume caused by this toxin. This
protective effect can be probably related to the inhibition of excitotoxic pathways. Thus, malonate induced the
activation of the calcium-dependent protease, calpain and the cyclin-dependent kinase 5, cdk5; which resulted
in the hyperphosphorylation of tau and the cleavage of the protective transcription factor, myocyte enhancer
factor 2, MEF2. All these effects were also signiﬁcantly reduced by sildenaﬁl pre-treatment, suggesting that
sildenaﬁl protects against malonate-induced cell death through the regulation of the calpain/p25/cdk5 signaling
pathway. Similar ﬁndings were obtained using inhibitors of calpain or cdk5, further supporting our contention.
Sildenaﬁl also increased MEF2 phosphorylation and Bcl-2/Bax and Bcl-xL/Bax ratios, effects that might as well
contribute to prevent cell death. Finally, sildenaﬁl neuroprotection was extended not only to rat hippocampal
slices subjected to oxygen and glucose deprivation when added at the time of reoxygenation, but also, in vivo
when administered after malonate injection. Thus, the therapeutic window for sildenaﬁl against malonate-
induced hypoxia was set at 3 h.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Phosphodiesterase 5 (PDE5) is a selective enzyme that catalyzes
the breakdown of the cyclic guanosine monophosphate, cGMP [1]
and has been found in several tissues and some brain regions [2,3]., cyclin-dependent kinase 5;
hrome c; DG, dentate gyrus;
artery occlusion; MDL28170,
nhancer factor 2; OGD, oxygen
PDE5, Phosphodiesterase 5;
; ROS, reactive oxygen species;
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rights reserved.Neuroprotective effects of PDE5 inhibitors (PDE5i), such as sildenaﬁl,
have been described in several models of neurological disorders. Lately,
and encouraged by the results obtained in several organs [4,5], new
studies are focusing on the potential role of sildenaﬁl, and other
PDE5i, in the treatment of cerebral ischemia. Indeed, recent reports
have shown that delayed treatment with PDE5 inhibitors increases
neurogenesis, angiogenesis, and synaptogenesis, and improves func-
tional outcome after stroke in young and aged rats [3,6–11]. Based on
these ﬁndings, safety studies in ischemic stroke patients are being
conducted prior to investigating the neurorestorative properties of sil-
denaﬁl in humans [12].
Despite all these evidences, there are few studies regarding the
mechanism underlying the beneﬁcial effects exerted by sildenaﬁl in
brain ischemic stroke models. The present study was, therefore, un-
dertaken to assess the plausible neuroprotective effects of sildenaﬁl
against chemical hypoxia caused by malonate, a reversible inhibitor
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mitochondrial toxin produces both energy depletion and lesions that
share many features with those that accompany focal ischemia [13].
The mechanisms of malonate-induced neuronal cell death comprise
the generation of reactive oxygen species, secondary excitotoxicity
and apoptosis [14,15].
Excitotoxiciy has been associated with neuronal death in brain
ischemia through the deregulation of speciﬁc cell signaling pathways
[16,17]. Among them, aberrant activation of the cyclin-dependent
kinase 5, cdk5, is directly associated with neuronal death following
stroke [18,19]. A main step in cdk5 deregulation is the cleavage of
its activator protein p35 by calpains, a group of calcium-activated cy-
tosolic proteases [20–23]. Since calpain and cdk5 have been proposed
as potential targets for the treatment of stroke [18,24,25], we focused
our study on this intracellular signaling pathway as a plausible target
for the neuroprotective effects of sildenaﬁl against malonate-induced
chemical hypoxia. Finally, we also used an in vitro brain ischemia–
reperfusion model, namely rat hippocampal slices subjected to oxy-
gen and glucose deprivation (OGD) followed by reoxygenation to
assess whether this PDE5i would have therapeutic result when admin-
istrated after the insult. Positive ﬁndings led us to establish its therapeu-
tic window against malonate-induced cell death; which was set at 3 h
post insult.
2. Experimental procedures
2.1. Drugs and chemicals
Sodium malonate dibasic monohydrate was from Sigma-Aldrich
(Madrid, Spain); carbobenzoxy-valinyl-phenylalaninal, MDL 28170,
calpain inhibitor III and 2-(R)-(1-Ethyl-2-hydroxyethylamino)-
6-benzylamino-9-isopropylpurine, roscovitine, cdk5 inhibitor were
from Calbiochem (Darmstadt, Germany); 1-[4-ethoxy-3-(6,7-
dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d]pyrimidin-5yl)
phenylsulfonyl]-4-methylpiperazine citrate (Sildenaﬁl citrate, Viagra™)
was from Pﬁzer.
2.2. In vivo studies
2.2.1. Animals, treatments, and experimental design
Experiments were carried out in male Wistar rats (220–270 g;
Harlan Iberica, Barcelona, Spain). Rats (four per cage) were housed
in constant conditions of humidity and temperature (22±1 °C)
with a 12-h/12-h light–dark cycle (lights on at 7:00 h). Food and
water were available ad libitum. The experiments were performed
after approval of the protocol by the institutional Ethics Committee,
in accordance with the law in force (European Directive 86/609/EEC
and Real Decreto 1201/2005), following the Research Council's
Guide for the Care and Use of Laboratory Animals. All efforts were
made to minimize animal suffering and to reduce the number of ani-
mals used in the experiments.
Rats were anesthetized with sodium pentobarbital (60 mg/kg i.p.)
and placed in a Kopf stereotaxic frame, with the incisor bar set at
3.3 mmbelow the interaural line. The skull was exposed, bregmapoint-
ed, and two holes were drilled at coordinates according to the atlas of
Paxinos and Watson [26]: +0.6 mm AP, ±3 mm ML. Animals were
injected with 2 μL of malonate, MDL 28170 or roscovitine using a
10-μL Hamilton syringe with a 26-gauge needle lowered 5.5 mm from
the skull. After injection, the needle was left in place for 2 min to
allow complete diffusion of the injected volume.
In a ﬁrst set of experiments, malonate (1.5 μmol in 2 μL, pH 7.4–7.6)
or PBS was infused into the striatum and animals were sacriﬁced at
different time points (10 min, 30 min, 1, 3, 6 or 9 h) for western blot
analysis. In an attempt to elucidate the mechanisms underlying silden-
aﬁl neuroprotection, rats were also administered orally with saline or
sildenaﬁl (1.5 mg/kg) 30 min before malonate or PBS injection andsacriﬁced 6 h or 72 h after treatment for western blot and histochemis-
try analysis.
In a different set of experiments, the calpain inhibitor, MDL28170
(1 nmol in 2 μL, pH 7.4–7.6 in DMSO 50%) or the cdk5 inhibitor,
roscovitine (40 nmol in 2 μL, pH 7.4–7.6 in DMSO 50%), alone or in
combination with malonate (1.5 μmol DMSO 50%), was also injected
into the striatum and animals were killed 6 h or 72 h after treatment.
Note that the sham group received 2 μL of DMSO 50%.
Finally, rats were orally administered with saline or sildenaﬁl
(1.5 mg/kg) and were sacriﬁced at different time points (3, 6, 12 or
24 h) to analyze the levels of Bcl-2, Bcl-xL and Bax in the striatum.
In order to establish the therapeutic window of sildenaﬁl, we also
infused malonate (1.5 μmol in 2 μL) or PBS into the striatumwhile sa-
line or sildenaﬁl (1.5 mg/kg) was administered intraperitoneally at
different time points (−30 min, +10 min, +1 h, +3 h, and +6 h).
Animals were sacriﬁced 72 h after treatment for histochemistry
analysis.
In all cases, the solution of sildenaﬁl was prepared as previously
described [27] by grinding Viagra™ tablets into powder and dissolved
in distilled water. The drug solution was ﬁltered (0.45 μm pore size)
before oral administration. Dose was chosen to simulate the dose
for a patient with 70 kg body weight after orally taking a 20 mg tablet
of Viagra™ according to Reagan-Shaw, Nihal and Ahmad [28] and is
the same that has been demonstrated to increase hippocampal and
striatal cGMP levels in rats 1 h after its administration [29].
2.2.2. Cytochrome oxidase histochemistry and analysis of lesion size
Seventy-two h after treatments, rats were killed and brains were
frozen immediately on dry ice and then sectioned (25 μm) on a cryo-
stat. Every second section throughout the extent of the lesion was
mounted on a polylysine-coated slide. Incubation medium consisted
of 5 mg cytochrome c and 30 mg 3,3′-diaminobenzidine in 50 mL of
0.1 M phosphate buffer, pH 7.4. Slides were incubated for 90 min at
37 °C and then removed to 4% neutral, buffered paraformaldehyde
for 10 min. Sections were rinsed with distilled water, dehydrated,
cleared in xylene, and coverslipped [30]. The lesioned area on each
section was quantiﬁed using a video-based MCID image analysis sys-
tem (Imaging Research, St. Catherines, Ontario, Canada). Area mea-
surements were summed and multiplied by intersectional distance
(50 μm) to determine lesion volume.
2.2.3. Subcellular fractionation and western blot analysis
For western blot analysis, animals were killed by decapitation;
brains were rapidly removed, placed on ice and 2 mm thick tissue
section was taken (approximately 1 mm to either side of the injection
zone). Striatal tissue was dissected out and fractionated into cytosolic
and nuclear fractions according to established protocols [31–33], with
some modiﬁcations. Brieﬂy, tissues were gently homogenized by 20
strokes in a glass-Teﬂon Potter homogenizer on ice in 200 μL of buffer
A (10 mM Tris, pH 7.4, 320 mM sucrose, 1 mM EDTA, 1 mM DTT,
and 1 mg/mL fatty-acid-free bovine serum albumin, BSA) containing
phosphatase inhibitors (Phosphatase Inhibitor Cocktail I, Sigma-Aldrich,
Madrid, Spain) and protease inhibitors (Protease Inhibitor Cocktail
Set I, Animal-Free Aprotinin, Calbiochem, Darmstadt, Germany).
Homogenateswere then centrifuged at 1500 g for 5 min at 4 °C. Pel-
lets were resuspended in 80 μL of buffer B (150 mMNaCl, 10 mM Tris,
pH 8.5, 1.5 mMMgCl, 0.5%Nonidet, 1 mMDTT, containingphosphatase
and protease inhibitors) andwere centrifuged twice at 1500 g for 5 min
at 4 °C to obtain the nuclear fraction. Supernatants were centrifuged at
15,000 g for 20 min at 4 °C. The resulting pellets were designatedmito-
chondrial fractions, whereas supernatants were further centrifuged
(100,000 g for 1 h at 4 °C) and saved as cytosolic (S100) fractions. The
mitochondrial fraction was further resuspended in 40 μL of buffer A
without BSA and centrifuged twice at 10,000 g for 20 min at 4 °C to ob-
tain the enrichedmitochondrial fraction. To verify the relative subcellu-
lar puriﬁcation, each fraction was subjected to western blotting for
Fodrin 30’Sham 10’ 1 6
Malonate
3
Total
145-150
9 hours
A
B
C
O
.D
. 1
45
-
15
0 
(%
 M
alo
na
te)
Malonate
0
25
50
75
100
125
+
Sildenafil
Sh
am
Si
ld
en
af
il
Malonate
Sildenafil
+
Malonate
Fodrin
Total
145-150
# # #
Malonate
+
Sildenafil (-30 min)Malonate
Le
si
on
 v
ol
um
e 
 (m
m3
)
Malonate
0
10
20
15
25
5
+ 
Sildenafil
# # #
102
102
Fig. 1. Sildenaﬁl protects against malonate-induced neurotoxicity and inhibits calpain activation. Panel A. Sildenaﬁl (1.5 mg/kg p.o.) was administered 30 min before intrastriatal
administration of malonate (1.5 μmol/2 μL). Rats were killed 72 h later. Representative cytochrome oxidase-stained slices and quantiﬁcation of malonate-induced striatal lesions
(mm3) show that the neurotoxic effect of malonate is attenuated by sildenaﬁl. Data are mean±S.E.M. (n=9 animals per group). [t (16)=6.452, Pb0.001]. Panel B. Animals
were sacriﬁced at different time points after intraestriatal injection of malonate (1.5 μmol/2 μL). Representative western blots of the time course activation of calpain induced
by malonate. Activation of calpain is demonstrated by increased levels of speciﬁc calpain-cleaved α-fodrin fragments (145–150 kDa). (n=5 per group). Panel C. Quantitative mea-
surement of protein levels and representative western blots showing the effect of sildenaﬁl on malonate-induced calpain activation. Sildenaﬁl (1.5 mg/kg p.o.) was administered
30 min before intrastriatal administration of malonate (1.5 μmol/2 μL) and animals were sacriﬁced 6 h after treatments. β-actin was used as equal loading control. Note that values
of cleaved α-fodrin (145–150 kDa) from the sham and sildenaﬁl groups were so weak that they were not taken into account for statistical analysis. Data are mean±S.E.M. (n=5
animals per group). [t(8)=6.202; Pb0.001]. ###Pb0.001 vs. malonate.
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solic marker, cytochrome c oxidase, COX (MitoSciences, Eugene, OR) as
amitochondrialmarker and LaminA/C (2032 Cell Signaling Technology,
Beverly, MA) as a nuclear marker.
For MEF2 and p-MEF2 determinations at 72 h and for Bcl-2, Bcl-xL
and Bax, tissues were homogenized as previously described [34] to ob-
tain whole cell extracts. Finally, protein was determined by Bradford
protein assay (Bio-Rad, Hercules, CA, USA).
Proteins (20 μg) were separated by electrophoresis on a sodium
dodecyl sulfate polyacrylamide gel under reducing conditions. Mem-
branes were probed using anti pMEF2 (Ser59)-R, anti-MEF2 (N-18)
(13919 and 13917, respectively; Santa Cruz Biotechnology, Santa
Cruz, CA); anti-pTau AT8 (MN1020 Pierce Biotechnology, Inc. Rockford,
USA); anti-Bax, anti-Bcl-2, anti-CDK5, anti-Lamin A/C; anti-P35/P25,
anti-Tau (clone Tau46) (2772, 2876, 2506, 2032, 2680, 4029, respec-
tively; Cell Signaling Technology, Beverly, MA), 1/1000 dilution or
anti-β-actin monoclonal antibody (A1978; Sigma, Madrid, Spain)
anti-COX subunit IV (MS404, MitoSciences, Eugene, OR), and anti-
α-fodrin (MAB1622, Chemicon, Millipore, Billerica, MA, USA), 1/10,000
dilution. Blots were visualized using a chemiluminescense ECL westernblotting detection reagent (Amersham, Buckinghamsire, England).
Band intensity was estimated densitometrically on a GS-800 cali-
brated densitometer (Biorad One).
2.3. In vitro studies
2.3.1. Hippocampal slices preparation
We used the protocol described by Egea and co-workers [35] with
slight modiﬁcations. Male Sprague–Dawley rats (275–325 g) were
quickly decapitated under sodium pentobarbital anesthesia (60 mg/kg,
i.p.), forebrains were rapidly removed from the skull and placed
into ice-cold Krebs bicarbonate dissection buffer (pH 7.4), containing
(in mM): NaCl 120, KCl 2, CaCl2 0.5, NaHCO3 26, MgSO4 10, KH2PO4
1.18, glucose 11 and sucrose 200. The chamber solutions were
pre-bubbled with either 95% O2/5% CO2 or 95% N2/5% CO2 gas mixtures
for at least 45 min before slice immersion, to ensure O2 saturation or
removal respectively. The hippocampi were quickly dissected and sec-
tioned in transverse slices of 350 (MTT assay) or 200 μm thick (Fluores-
cence and LDH assays) using a chopper (Mc Ilwain Tissue Chopper, The
Micle Laboratory Engineering Company). After an initial stabilization
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Fig. 2. Sildenaﬁl inhibits malonate-induced p25/cdk5 pathway activation. Sildenaﬁl (1.5 mg/kg p.o.) was administered 30 min before intrastriatal administration of malonate
(1.5 μmol/2 μL). Rats were sacriﬁced 6 h after treatments. Panel A. Quantitative measurements and representative blots showing that sildenaﬁl reverses malonate-induced cleavage
of p35 to p25. β-actin was used as equal loading control. Note that p25 values from the sham and sildenaﬁl groups were so weak that were not taken into account for statistical
analysis. Data are mean±S.E.M. (n=5 animals per group). [t(8)=3.997; Pb0.001]. Panel B. Quantitative measurement and representative blots of cdk5 levels in both cytosolic
and nuclear fractions showing that sildenaﬁl reverses malonate-induced cdk5 translocation. Note that nuclear values from the sham and sildenaﬁl groups were so weak that
were not taken into account for statistical analysis. β-actin and lamin A/C were used as equal loading control. (n=5–8 per group). Statistical analysis yielded the following results:
for cytosolic cdk5 [F(3,17)=22.08; Pb0.001] and for nuclear cdk5 [t(10)=2.703, Pb0.05]. Panel C. Representative blots showing the purity of our samples. ***Pb0.001 vs. sham;
#Pb0.05, ##Pb0.01, ###Pb0.001 vs. malonate.
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bated 15 min in a Krebs solution with the following composition
(in mM): NaCl 120, KCl 2, CaCl2 2, NaHCO3 26, MgSO4 1.19, KH2PO4
1.18 and glucose 11; this solution was equilibrated with 95% O2/5%
CO2. Oxygen and glucose deprivation was induced by incubating the
slices for 15 min period in a glucose-free Krebs solution, equilibrated
with a 95% N2/5% CO2 gas mixture; glucose was replaced by
2-deoxyglucose. After this OGD period, slices were returned back to an
oxygenated normal Krebs solution containing glucose (reoxygenation
period) for 2 h in the absence or presence of sildenaﬁl (10 μM).
In all experiments sildenaﬁl was only present during the 2 h
reoxygenation period (see protocol in Fig. 8A). Experiments were
performed at 37 °C. A control and an OGD/reoxygenation group
were included in all experiments.
2.3.2. Quantiﬁcation of cell death
Hippocampal cell viability was determined through the ability of
the cells to reduce MTT [36] and also bymeasuring the activity of lac-
tate dehydrogenase (LDH) released into the incubation media [37],using a commercial kit (Cytotoxicity Detection Kit, Roche) and fol-
lowing the manufacturer's indications.
2.3.3. Quantiﬁcation of cell death in propidium iodide (PI) stained
hippocampal slices
At the end of the experiment, the hippocampal slices were loaded
with 5 μg/mL PI during the last 5 min of incubation. Mean PI in CA1,
CA3 and dentate gyrus (DG) regions in each slice, after a given treat-
ment, were analyzed.
2.3.4. Measurement of ROS production in hippocampal slices
Tomeasure cellular reactive oxygen species (ROS), we used themo-
lecular probe H2DCFDA [38]. Immediately after chopper sectioning,
200 μm thick hippocampal slices were loaded with 80 μM H2DCFDA
for 45 min in Krebs solution. Subsequently, the slices were washed
twice with Krebs solution and OGD/Reox protocol started.
Fluorescence was measured in a ﬂuorescence inverted NIKON
eclipse T2000-U microscope. Wavelengths of excitation and emission
for PI were 530 and 580 respectively and 485 and 520 nm for
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Fig. 3. Calpain inhibition protects frommalonate-induced neurotoxicity. MDL28170 (1 nmol/2 μL) was administered intrastriatally in combination withmalonate (1.5 μmol/2 μL). Panel
A. Quantitative measurements and representative blots showing that MDL28170 inhibits not only calpain activation, but also the cleavage of p35 to p25 and the translocation of cdk5 to
the nucleus. For this, rats were killed 6 h after treatment. β-actin and lamin A/C were used as equal loading control. Note that some values from the sham and sildenaﬁl groups
were so weak that they were not taken into account for statistical analysis. Data are mean±S.E.M. (n=5–9 animals per group). Statistical analysis yielded the following results:
for fodrin breakdown products [t(8)=2.771; Pb0.05]; for p25/p35 [t(10)=2.452; Pb0.05]; for cytosolic cdk5 [F(3,19)=10.95; Pb0.001] and for nuclear cdk5 [t(11)=5.123;
Pb0.001] Panel B. Representative cytochrome oxidase-stained slices and quantiﬁcation of malonate-induced striatal lesions (mm3) show that MDL28170 inhibits the neurotoxic
effect of malonate observed 72 h after treatment. Data are mean±S.E.M. (n=7) [t(12)=5.346, Pb0.001]. Different from the corresponding sham group: ***Pb0.001. Different
from malonate-only animals: #Pb0.05; ##Pb0.01; ###Pb0.001.
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ﬁcations of 100×. Fluorescence analysis was performed using the
Metamorph programme version 7.0. Fluorescence in basal conditions
was taken as 1 and experimental variables were normalized with
respect to this value.2.4. Data analysis
Results were expressed as mean±S.E.M. Comparisons among
groups were made using Student's t-test or one-way analysis of vari-
ance followed by Tukey test for multiple group comparisons. Treatment
differences were considered statistically signiﬁcant at pb0.05. Data
analyses were performed using the Statistical Program for the Social
Sciences (SPSS for Windows, 15.0; SPSS, Chicago, IL, USA).3. Results
3.1. Sildenaﬁl protects againstmalonate-induced neurotoxicity and inhibits
calpain activation
Rats were administered with sildenaﬁl (1.5 mg/kg p.o.) 30 min be-
fore striatal stereotaxic injection of malonate (1.5 μmol) to investigate
its neuroprotective effects against neuronal death caused by this mito-
chondrial toxin. Rats were killed 72 h later and the tissue was prepared
for histochemistry. As shown in Fig. 1A, malonate produced a large
striatal lesion that was signiﬁcantly reduced in those animals receiving
sildenaﬁl.
It has been suggested that excitotoxicity plays a key role in the
mechanisms underlying malonate neurotoxicity [15,30]. We there-
fore studied the time course activation of calpain, one of the major
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Animals were sacriﬁced 72 h after malonate injection. Data are mean±S.E.M. (n=5–6). [t(9)=3.301, Pb0.01]. Different from the corresponding sham group: **Pb0.01. Different
from malonate-only animals: #Pb0.05; ##Pb0.01; ###Pb0.001.
710 L. Barros-Miñones et al. / Biochimica et Biophysica Acta 1832 (2013) 705–717effectors of calcium deregulation [17,39,40]. For this, we examined
the breakdown products of α-fodrin, a sensitive substrate for calpain,
at different time points after malonate. As shown in Fig. 1B, α-fodrin
breakdown products accumulated in a time-dependent manner. In
particular, calpain speciﬁc 145–150 kDa α-fodrin fragments began
to accumulate by 30 min after malonate, reaching its maximum be-
tween 6 to 9 h later. In parallel, the intensity of the full-length protein
(280 kDa) was reduced. Based on these results, we next investigated
whether sildenaﬁl affected the activation of this protease. In this case,
rats were killed 6 h after malonate, as we had observed a sustained
increase of calpain at this time point. Noteworthy, sildenaﬁl signiﬁ-
cantly reduced calpain activation (Fig. 1C).
3.2. Sildenaﬁl inhibits malonate-induced cdk5 activation and its translo-
cation to the nucleus
Under pathological conditions, calpain cleaves p35 to its more
stable isoform, p25. Cleavage of p35 to p25 and formation of thep25/cdk5 complex are associated with the pathologic activity of
cdk5 and the alteration of its subcellular distribution [22,41]. As
shown in Fig. 2A, western blot analysis revealed a signiﬁcant increase
in the p25/p35 ratio in the striatum of animals treated with malonate,
an effect that was signiﬁcantly reduced by sildenaﬁl. Next, we mea-
sured cdk5 levels in cytoplasmic and nuclear fractions and found
that sildenaﬁl reversed the translocation of cdk5 to the nucleus in-
duced by malonate (Fig. 2B). Both measurements were carried out
6 h after malonate administrations.
3.3. Calpain inhibition protects against malonate-induced cell death
To evaluate whether calpain inhibition participates in the mecha-
nisms underlying sildenaﬁl protection, in parallel experiments, we in-
vestigated whether the inhibition of this protease would result in the
corresponding decrease of malonate neurotoxicity. For this, rats were
treated with the speciﬁc calpain inhibitor, MDL28170 [42], in combi-
nation with malonate. As seen in Fig. 3A, the co-administration of
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711L. Barros-Miñones et al. / Biochimica et Biophysica Acta 1832 (2013) 705–717MDL28170 (1 nmol/2 μL) resulted in a signiﬁcant decrease of α-fodrin
breakdownproducts, indicating an effective blockage of calpain activity.
This effect was accompanied by a decrease of p35 cleavage and the in-
hibition of cdk5 translocation to the nucleus. Moreover, calpain inhibi-
tion decreased neuronal death caused by malonate administration,
assessed by cytochrome oxidase histochemistry (Fig. 3B).
3.4. Cdk5 inhibition protects against malonate-induced cell death
In order to evaluate the involvement of cdk5 in the neurotoxic
mechanisms triggered by malonate, we used roscovitine, an inhibitor
of this kinase [43], in combination with malonate. Treatment with
roscovitine (40 nmol/2 μL) not only inhibited the activation of cdk5
and its translocation to the nucleus but also blocked the activation of
calpain (Fig. 4A). Moreover, the signiﬁcance of p25/cdk5 in malonate-
induced neuronal death was also conﬁrmed since roscovitine signiﬁ-
cantly decreased the histological lesion found after malonate adminis-
tration (Fig. 4B). These results not only support the key role of theaberrant activation of cdk5 in malonate neurotoxicity but also point to
its inhibition by sildenaﬁl as a plausible mechanism underlying its
cytoprotective effects.3.5. Sildenaﬁl prevents tau hyperphosphorylation caused by malonate
Since p25-activated cdk5 has been suggested to participate in the
hyperphosphorylation of tau [20], we analyzed the phosphorylation
status of this microtubule associated protein in malonate-injured rats
and in animals pre-treated with sildenaﬁl. We used the phospho-tau
antibody, AT8, which recognizes aberrantly phosphorylated epitopes
on Ser202/Thr205 and which is considered to be the most appropriate
antibody to measure cdk5-induced tau phosphorylation [44]. As
shown in Fig. 5A, western blot analysis revealed that phosphorylated
tau levels that normalized to total tau (detected by T46 antibody)
were signiﬁcantly increased 6 h after malonate injection; an effect
that was signiﬁcantly reduced by sildenaﬁl.
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712 L. Barros-Miñones et al. / Biochimica et Biophysica Acta 1832 (2013) 705–717As we have previously conﬁrmed that activation of calpain
and cdk5 is required for malonate-induced neurotoxicity, we also
analyzed the implication of both proteins on malonate-induced
tauopathy. Fig. 5B and C demonstrate that administration of either
MDL28170 or roscovitine in combination with malonate signiﬁcantly
attenuated tau hyperphosphorylation.
3.6. Sildenaﬁl inhibits MEF2 cleavage induced by malonate
The phosphorylation at serine 59 of the transcription factor
myocyte enhancer factor 2 (MEF2) increases its survival promoting
activity [45]. By contrast, the translocation of cdk5 to the nucleus
leads to its degradation, an effect associated to neuronal death in
stroke models [46]. Based on our previous results we analyzed total
and p-MEF2 (ser59) levels 6 h after malonate. Although we had
previously shown that cdk5 translocates to the nucleus by this time,we did not ﬁnd any effect of malonate on total or p-MEF2 levels.
Of notice, sildenaﬁl signiﬁcantly enhanced the phosphorylation of
MEF2 at ser 59 (Fig. 6A). To further investigate the integrity of
MEF2, we next decided to prepare whole cell lysates from animals
treated with malonate 72 h before. As shown in Fig. 6B, levels of
both, phosphorylated and total protein, decreased in the malonate-
injured group, an effect signiﬁcantly reversed by sildenaﬁl. A plausi-
ble explanation for such ﬁndings could be attributed to the inhibition
of cdk5 activation and its translocation to the nucleus since roscovitine
produced similar results (Fig. 6C).
3.7. Sildenaﬁl increases the expression of Bcl-2 and Bcl-xL
Some authors have previously demonstrated that malonate
causes the activation of apoptotic pathways [47–49]. For this reason,
we next studied the subcellular location of two proteins implicated
713L. Barros-Miñones et al. / Biochimica et Biophysica Acta 1832 (2013) 705–717in apoptosis, namely Bax and cytochrome c (cyt c), 10 min, 30 min,
1, 3, 6 or 9 h after malonate injection. Bax, which normally resides
in the cytosol, promotes apoptosis by translocating to the mitochon-
dria which leads to the subsequent release of cyt c [50–52]. In con-
trast to those previous studies, we did not ﬁnd any change on the
subcellular location of either protein at any time point. Fig. 7A
shows the results obtained 6 h after malonate injection.
In parallel, we evaluated the effect of sildenaﬁl on two antiapoptotic
proteins, Bcl-2 and Bcl-xL. For this, a single dose of sildenaﬁl (1.5 mg/kg,
p.o.) was administered and rats were sacriﬁced at different time points
(0, 3, 6, 12 and 24 h after treatment). As shown in Fig. 7B, sildenaﬁl en-
hanced the levels of Bcl-2 and Bcl-xLwhereas no changes in Bax expres-
sion were observed. The Bcl-2/Bax ratio reached its maximum level at
24 h while the Bcl-xL/Bax ratio was increased only at 6 and 12 h after
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Fig. 7. Sildenaﬁl increases the expression of Bcl-2 and Bcl-xL. Panel A. Rats were adminis-
tered intrastriatally withmalonate (1.5 μmol/2 μL) and sacriﬁced at different time points.
Representative western blots showing no changes on Bax or cit c subcellular location 6 h
aftermalonate injection. Panel B. Rats were sacriﬁced at different time points after a single
dose of sildenaﬁl (1.5 mg/kg p.o.). Quantitative measurements and representative blots
showing that sildenaﬁl increases expression of Bcl-2 and Bcl-xL. No effect on Bax expres-
sion was observed. β-actin was used as equal loading control.3.8. Sildenaﬁl reduces cell death of hippocampal slices subjected to
OGD/reoxygenation
Sildenaﬁl added to the incubation medium post-OGD (see proto-
col in Fig. 8A) afforded a signiﬁcant cell protection revealed by a par-
tial recovery of MTT metabolism reduction found in hippocampal
slices subjected to OGD/reox (Fig. 8B). These results were in accor-
dance with LDH measurements. While OGD/reox protocol almost
doubled the amount of LDH released to the incubation medium, sil-
denaﬁl decreased this amount by 50% (Fig. 8C). Finally, when cell vi-
ability was measured by PI ﬂuorescence (Fig. 8D), there was an
approximately two-fold increase in the CA1, CA3 and the dentate
gyrus (DG) due to OGD/reox that was reduced by sildenaﬁl in the
CA1 and in the DG but not in the CA3 region of the hippocampus.
As expected, ROS production was increased in the OGD/reox group
at the end of the 2 h reoxygenation period. Although there was a
trend towards reduction in ROS production, sildenaﬁl addition did
not produce any beneﬁcial effect in any of the hippocampal areas
studied (Fig. 8E).
3.9. Therapeutic window of sildenaﬁl
Based on the protective effects of sildenaﬁl against OGD/reoxwe de-
cided to addresswhether itwould also result in neuroprotection if given
after malonate injections and to establish its therapeutic window. For
these experiments, sildenaﬁl was administered intraperitoneally in-
stead of orally because rats were still under the effects of anesthesia.
Analysis of lesion volumes revealed that sildenaﬁl afforded a signiﬁcant
protection againstmalonate-induced neuronal death up to 3 h after the
toxic insult (Fig. 9).
4. Discussion
Based on the positive results shown by PDE5 inhibitors against is-
chemia in several organs [4,5], studies are focusing on the therapeu-
tic potential of this type of drugs for the treatment of cerebral stroke.
Indeed, recent reports have shown that delayed sildenaﬁl adminis-
tration improves functional recovery in rats after stroke by enhanc-
ing angiogenesis, neurogenesis and improving neurologic function
[6,7,9,10]. In the present work we now report that sildenaﬁl affords
a signiﬁcant protection against malonate-induced cell death, an ef-
fect still evident if administered up to 3 h after the toxic insult.
Such beneﬁcial effects appear to be mediated by the regulation of
the calpain/p25/cdk5 signaling pathway. Moreover, increased phos-
phorylation of the prosurvival transcription factor MEF2 and the
up-regulation of Bcl-2/Bax and Bcl-xL/Bax ratios caused by sildenaﬁl
may as well account for its neuroprotective effects.
Malonate, a reversible inhibitor ofmitochondrial succinate dehydro-
genase (SDH), produces a cell loss that mimicsmany of the biochemical
and neuropathological features of stroke [13,53]. In fact, malonate can
trigger the generation of superoxide radicals, secondary excitotoxicity
mediated by Ca2+ inﬂux and apoptosis [14,15]. Under our experimental
conditions, malonate produced histological lesions that were signiﬁ-
cantly reduced by sildenaﬁl. We had previously found no effect of sil-
denaﬁl on ROS production [54], for this reason we focused our work
on the other two mechanisms implicated in malonate neurotoxicity,
namely excitotoxicity and apoptosis. Excitotoxicity has been postulated
to underlie neuronal death due to cerebral ischemia [55] as well as a
number of neurodegenerative disorders [56–58]. Activation of calpains
is a major effector in the excitotoxic signal transduction cascade
[39,59,60], and has been shown to be selectively activated in striatal
neurons after malonate administration [61]. In agreement with this lat-
ter report, calpain activity was enhanced by malonate treatment, as
demonstrated by increased levels of speciﬁc calpain-cleaved fodrin
breakdown products, which began to accumulate as early as 30 min
and maximized between 6 and 9 h after malonate. As demonstrated
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714 L. Barros-Miñones et al. / Biochimica et Biophysica Acta 1832 (2013) 705–717by our data, sildenaﬁl signiﬁcantly reversed the activation of calpain in-
duced bymalonate, an effect independent of any direct inhibition of this
protease by sildenaﬁl [27].
Once activated, calpain is known to deregulate the normal function
of cdk5. The activity of this kinase is regulated by the binding of one
of its activator proteins, p35 or p39, which are cleaved by calpain
[21,22,62]. Calpain-mediated truncation of p35 to p25 produces a
more stable and active form of the protein, the p25/cdk5 complex,
with an altered subcellular distribution [20,63]. Aberrant activation of
cdk5 following ischemic stroke is a key process leading to neuronal
cell death [18,19,46,61,64]. Of interest, this pathway has also been asso-
ciated with damaged neurons in brain tissue from stroke-affected pa-
tients [65]. In our model, malonate produced a signiﬁcant increase of
p25 thatwas accompanied by the translocation of cdk5 from the cytosol
to the nucleus, effects that were signiﬁcantly reduced by sildenaﬁl. The
implication of the calpain/p25/cdk5 pathway on malonate-induced celldeath was further conﬁrmed by using inhibitors of calpain or cdk5;
which also afforded a signiﬁcant protection against the toxic effects
of malonate. Of interest, roscovitine also inhibited the activation of
calpain. Such effect could be explained by the fact that the p25/cdk5
complex is known to phosphorylate NMDA receptors, thereby amplify-
ing calcium inﬂux and increasing the activation of excitotoxicmolecular
cascades [66].
Cdk5 overactivation by binding to p25 changes its substrate speciﬁcity
producing the hyperphosphorylation of substrates not normally phos-
phorylated by this kinase and triggering a cascade of neurotoxic pathways
[63,67,68]. Among other potential targets, the microtubule-associated
protein tau has been proposed to be hyperphosphorylated by cdk5 fol-
lowing focal ischemia [69,70]. Taking this into account, we then analyzed
tau phosphorylation. Malonate-treated animals showed an increased
phosphorylation of tau at Ser202/Ser205 (AT8 epitope) that was success-
fully reverted by sildenaﬁl. Likewise, inhibition of calpain and cdk5 also
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Rats were killed 72 h later. Representative cytochrome oxidase-stained slices and
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this deregulated kinase pathway in malonate-induced cell death and in
sildenaﬁl afforded neuroprotection.+
Fig. 10. Proposed mechanisms underlying sildenaﬁl neuroprotection against malonate-indu
induces mitochondrial dysfunction, which results in calcium deregulation. The secondary ex
age to p25. The p25/cdk5 complex contributes to neuronal death by hyperphosphorylating
afforded protection appears to be related to the inhibition of the calpain/p25/cdk5 pathwayMyocyte enhancer factor 2 (MEF2) is a group of transcriptional
factors required to regulate neuronal development, synaptic plastici-
ty, as well as survival [71]. It has also been described that neurotoxic-
ity induces destabilization of MEF2s in neurons caused by an increase
in caspase-dependent cleavage of MEF2, an effect that requires nucle-
ar activation of cdk5 activity [72–75]. Despite the translocation of
cdk5 to the nucleus 6 h after malonate injection, we did not ﬁnd
any effect on MEF2 levels at this time point. It should be noted, how-
ever, the large decrease in MEF2 levels 72 h after malonate adminis-
tration suggesting the possible cleavage and inactivation of this
protein at some time point between 6 and 72 h. This effect was
prevented by both, sildenaﬁl and roscovitine, further supporting the
regulation of calpain/Cdk5/p25 by sildenaﬁl as a plausible mechanism
underlying its cytoprotective properties. As a critical survival protein,
MEF2s are tightly regulated via posttranslational modiﬁcations. It is
known that phosphorylation by kinases is an important process
through which the activity of MEF2 is up- or down-regulated
[76–78]. In this sense, phosphorylation of MEF2 at ser59 enhances
its binding to the DNA and, consequently, its transcriptional activity
[45,79]. Of interest, p-MEF2 (ser59) levels were signiﬁcantly in-
creased in sildenaﬁl-treated rats what could represent a new surviv-
al pathway activated by sildenaﬁl with important implications to our
model, as restoration of the active form of MEF2 has been proved to
be protective following focal ischemia [46].
We also found that sildenaﬁl increased the levels of the antiapoptotic
proteins Bcl-2 and Bcl-xL in the striatum. The Bcl2 family of proteins is
implicated in the regulation of apoptosis and comprises members that
have either antiapoptotic or proapototic effects. While Bcl-2 and Bcl-xLced neurotoxicity. Inhibition of succinate dehydrogenase by malonate administration
citotoxicity leads to the activation of calpain, which, in turn, is responsible of p35 cleav-
tau in the cytosol and targeting MEF2 for its degradation within the nucleus. Sildenaﬁl
and the up-regulation of antiapoptotic proteins. —————, effect described by [66].
716 L. Barros-Miñones et al. / Biochimica et Biophysica Acta 1832 (2013) 705–717play a critical role in mediating survival signals [80]; activation of Bax, by
calpain cleavage, leads to cyt c release from the mitochondria to the
cytosol triggering apoptosis [50–52,81]. Although, we did not ﬁnd any
change in the subcellular location of Bax or cyt c 6 h aftermalonate injec-
tion, there is substantial evidence indicating that apoptosis is implicated
inmalonate-induced cell death [13,47,48,82,83], which prevents us from
ruling out the participation of apoptosis in ourmodel. Instead, our results
could be explained in terms of timing. In fact, activation of caspases was
not detectable earlier than 6 h after striatalmalonate injection [13] or be-
tween 12 and 24 h after in vitro malonate addition [47]. At these time
points after sildenaﬁl administration, Bcl-2/Bax and Bcl-xL/Bax ratios
were signiﬁcantly increased and it is known that Bcl-2 or Bcl-xL
overexpression is sufﬁcient to reduce malonate-induced apoptosis
[13,47,48], what provides another mechanism by which sildenaﬁl
might have afforded a signiﬁcant protection against malonate-induced
neurotoxicity. Although not directly addressed in this work, our group
andothers have previously shown that sildenaﬁl increasesAkt phosphor-
ylation in the brain [3,29]. Noteworthy, activated Akt stimulated changes
in Bcl-2 expression and showed antiapoptotic effects in several different
cell types, including the hippocampal neurons and PC12 cells [84,85].
Therefore the activation of Akt could be underlying the antiapoptotic
effects observed after sildenaﬁl administration in this model.
In the present study we also demonstrated that sildenaﬁl, at a con-
centration shown to protect adult cardiomyocytes against ischemia/
reperfusion injury [86], also protects hippocampal slices subjected
to OGD. Noteworthy, in these experiments sildenaﬁl was added at
the time of reoxygenation. Based on these ﬁndings and on the fact
that in the treatment of stroke the time window for administration
of neuroprotective agents is a critical issue, we next analyzed wheth-
er sildenaﬁl would also protect against malonate-induced cell death if
administered after the toxic insult, as in the OGD study. Sildenaﬁl was
effective when administered up to 3 h after striatal malonate injec-
tion. At this time point, NMDA antagonists, glutamate release inhibi-
tors [87] or cdk5 inhibitors (this work, unpublished data) are no
longer protective, what provides further signiﬁcance to our ﬁndings.
In conclusion, our results show that sildenaﬁl exerts neuroprotection
not only in an in vitromodel of OGD but also in amodel of chemical hyp-
oxia in vivo. This protective effect appears to be related to an inhibition
of the calpain/p25/cdk5 pathway. Furthermore, our data point to the
up-regulation of antiapoptotic and prosurvival proteins as other plausi-
ble mechanisms underlying sildenaﬁl neuroprotection (Fig. 10). Note-
worthy, sildenaﬁl showed an interesting therapeutic time window.
Future studies using other animal models of stroke are warranted in
order to exploit the possible therapeutic potential of sildenaﬁl in
preventing neuronal cell death following ischemia/reperfusion.
Disclosure Statement
None of the authors have any actual or potential conﬂict of interest
including any ﬁnancial, personal or other relationships with other peo-
ple or organizations within three years of beginning the work submit-
ted that could inappropriately inﬂuence their work.
Acknowledgements
The authors are grateful to Sandra Lizaso, Mari Luz Muro and
Vanessa Gómez-Rangel for technical assistance. They would also like
to thank “Amigos de la Universidad de Navarra” for a fellowship to
L.O. and L.B-M and Ramon Areces Foundation for a fellowship to E.P.
This work was supported by grants from the Ministerio de Ciencia e
Innovación (SAF2008-05143-C03-03).
References
[1] A.T. Bender, J.A. Beavo, Cyclic nucleotide phosphodiesterases: molecular regula-
tion to clinical use, Pharmacol. Rev. 58 (2006) 488–520.[2] A.T. Bender, J.A. Beavo, Speciﬁc localized expression of cGMP PDEs in Purkinje
neurons and macrophages, Neurochem. Int. 45 (2004) 853–857.
[3] L. Wang, Z. Gang Zhang, R. Lan Zhang, M. Chopp, Activation of the PI3-K/Akt
pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells
derived from the subventricular zone, J. Cereb. Blood Flow Metab. 25 (2005)
1150–1158.
[4] D. Kouvelas, A. Goulas, G. Papazisis, C. Sardeli, C. Pourzitaki, PDE5 inhibitors:
in vitro and in vivo pharmacological proﬁle, Curr. Pharm. Des. 15 (2009) 3464–3475.
[5] R.C. Kukreja, F.N. Salloum, A. Das, S. Koka, R.A. Ockaili, L. Xi, Emerging new uses of
phosphodiesterase-5 inhibitors in cardiovascular diseases, Exp. Clin. Cardiol. 16
(2011) e30–e35.
[6] G. Ding, Q. Jiang, L. Li, L. Zhang, Z.G. Zhang, K.A. Ledbetter, S. Panda, S.P. Davarani, H.
Athiraman, Q. Li, J.R. Ewing, M. Chopp, Magnetic resonance imaging investigation of
axonal remodeling and angiogenesis after embolic stroke in sildenaﬁl-treated rats,
J. Cereb. Blood Flow Metab. 28 (2008) 1440–1448.
[7] L. Li, Q. Jiang, L. Zhang, G. Ding, Z. Gang Zhang, Q. Li, J.R. Ewing, M. Lu, S. Panda,
K.A. Ledbetter, P.A. Whitton, M. Chopp, Angiogenesis and improved cerebral
blood ﬂow in the ischemic boundary area detected by MRI after administration
of sildenaﬁl to rats with embolic stroke, Brain Res. 1132 (2007) 185–192.
[8] F.S. Menniti, J. Ren, T.M. Coskran, J. Liu, D. Morton, D.K. Sietsma, A. Som, D.T.
Stephenson, B.A. Tate, S.P. Finklestein, Phosphodiesterase 5A inhibitors improve
functional recovery after stroke in rats: optimized dosing regimen with implica-
tions for mechanism, J. Pharmacol. Exp. Ther. 331 (2009) 842–850.
[9] R. Zhang, Sildenaﬁl (Viagra) induces neurogenesis and promotes functional re-
covery after stroke in rats, Stroke 33 (2002) 2675–2680.
[10] L. Zhang, R.L. Zhang, Y. Wang, C. Zhang, Z.G. Zhang, H. Meng, M. Chopp, Functional
recovery in aged and young rats after embolic stroke: treatment with a phospho-
diesterase type 5 inhibitor, Stroke 36 (2005) 847–852.
[11] R.L. Zhang, Z. Zhang, L. Zhang, Y. Wang, C. Zhang, M. Chopp, Delayed treatment
with sildenaﬁl enhances neurogenesis and improves functional recovery in
aged rats after focal cerebral ischemia, J. Neurosci. Res. 83 (2006) 1213–1219.
[12] B. Silver, S. McCarthy, M. Lu, P. Mitsias, A.N. Russman, A. Katramados, D.C. Morris,
C.A. Lewandowski, M. Chopp, Sildenaﬁl treatment of subacute ischemic stroke: a
safety study at 25-mg daily for 2 weeks, J. Stroke Cerebrovasc. Dis. 18 (2009)
381–383.
[13] J.B. Schulz, M. Weller, R.T. Matthews, M.T. Heneka, P. Groscurth, J.C. Martinou,
J. Lommatzsch, R. von Coelln, U. Wullner, P.A. Loschmann, M.F. Beal, J. Dichgans, T.
Klockgether, Extended therapeutic window for caspase inhibition and synergy
with MK-801 in the treatment of cerebral histotoxic hypoxia, Cell Death Differ. 5
(1998) 847–857.
[14] A. Dedeoglu, R.J. Ferrante, O.A. Andreassen, W.H. Dillmann, M.F. Beal, Mice
overexpressing 70-kDa heat shock protein show increased resistance to malonate
and 3-nitropropionic acid, Exp. Neurol. 176 (2002) 262–265.
[15] J.G. Greene, J.T. Greenamyre, Manipulation of membrane potential modulates
malonate-induced striatal excitotoxicity in vivo, J. Neurochem. 66 (1996) 637–643.
[16] M.M. Aarts, M. Arundine, M. Tymianski, Novel concepts in excitotoxic
neurodegeneration after stroke, Expert Rev. Mol. Med. 5 (2003) 1–22.
[17] M. Arundine, M. Tymianski, Molecular mechanisms of calcium-dependent
neurodegeneration in excitotoxicity, Cell Calcium 34 (2003) 325–337.
[18] M. Slevin, J. Krupinski, Cyclin-dependent kinase-5 targeting for ischaemic stroke,
Curr. Opin. Pharmacol. 9 (2009) 119–124.
[19] J. Rashidian, G. Iyirhiaro, H. Aleyasin, M. Rios, I. Vincent, S. Callaghan, R.J. Bland,
R.S. Slack, M.J. During, D.S. Park, Multiple cyclin-dependent kinases signals are
critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo,
Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14080–14085.
[20] G.N. Patrick, L. Zukerberg, M. Nikolic, S. de la Monte, P. Dikkes, L.H. Tsai, Conver-
sion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration,
Nature 402 (1999) 615–622.
[21] M.S. Lee, Y.T. Kwon, M. Li, J. Peng, R.M. Friedlander, L.H. Tsai, Neurotoxicity in-
duces cleavage of p35 to p25 by calpain, Nature 405 (2000) 360–364.
[22] G. Kusakawa, T. Saito, R. Onuki, K. Ishiguro, T. Kishimoto, S. Hisanaga, Calpain-
dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator
to p25, J. Biol. Chem. 275 (2000) 17166–17172.
[23] A. Camins, E. Verdaguer, J. Folch, M. Pallas, Involvement of calpain activation in
neurodegenerative processes, CNS Drug Rev. 12 (2006) 135–148.
[24] S. Timsit, B. Menn, Cerebral ischemia, cell cycle elements and Cdk5, Biotechnol.
J. 2 (2007) 958–966.
[25] B. Menn, S. Bach, T.L. Blevins, M. Campbell, L. Meijer, S. Timsit, Delayed treatment
with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5
activity increase in animal stroke models, PLoS One 5 (2010) e12117.
[26] G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press,
New York, 1997.
[27] E. Puerta, I. Hervias, L. Barros-Minones, J. Jordan, A. Ricobaraza,M. Cuadrado-Tejedor,
A. Garcia-Osta, N. Aguirre, Sildenaﬁl protects against 3-nitropropionic acid neuro-
toxicity through the modulation of calpain, CREB, and BDNF, Neurobiol. Dis. 38
(2010) 237–245.
[28] S. Reagan-Shaw, M. Nihal, N. Ahmad, Dose translation from animal to human
studies revisited, FASEB J. 22 (2008) 659–661.
[29] E. Puerta, I. Hervias, B. Goni-Allo, B. Lasheras, J. Jordan, N. Aguirre, Phosphodiesterase
5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deﬁcits
in the rat, J. Neurochem. 108 (2009) 755–766.
[30] B. Goni-Allo, M. Ramos, J. Jordan, N. Aguirre, In vivo studies on the protective role of
minocycline against excitotoxicity caused by malonate or N-methyl-d-aspartate,
Exp. Neurol. 191 (2005) 326–330.
[31] A. Garcia-Osta, J. Del Rio, D. Frechilla, Increased CRE-binding activity and tryptophan
hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine
717L. Barros-Miñones et al. / Biochimica et Biophysica Acta 1832 (2013) 705–717(MDMA, “ecstasy”) in the rat frontal cortex but not in the hippocampus, Brain Res.
Mol. Brain Res. 126 (2004) 181–187.
[32] F. Pallotti, G. Lenaz, Isolation and subfractionation of mitochondria from animal
cells and tissue culture lines, Methods Cell Biol. 80 (2007) 3–44.
[33] C. Vijayvergiya, M.F. Beal, J. Buck, G. Manfredi, Mutant superoxide dismutase 1
forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclero-
sis mice, J. Neurosci. 25 (2005) 2463–2470.
[34] B. Goni-Allo, E. Puerta, B.O. Mathuna, I. Hervias, B. Lasheras, R. de la Torre,
N. Aguirre, On the role of tyrosine and peripheral metabolism in 3,4-
methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats,
Neuropharmacology 54 (2008) 885–900.
[35] J. Egea, A.O. Rosa, M. Sobrado, L. Gandia, M.G. Lopez, A.G. Garcia, Neuroprotection
afforded by nicotine against oxygen and glucose deprivation in hippocampal
slices is lost in alpha7 nicotinic receptor knockout mice, Neuroscience 145
(2007) 866–872.
[36] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: applica-
tion to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983)
55–63.
[37] M. Sobrado, J.M. Roda, M.G. Lopez, J. Egea, A.G. Garcia, Galantamine and
memantine produce different degrees of neuroprotection in rat hippocampal slices
subjected to oxygen-glucose deprivation, Neurosci. Lett. 365 (2004) 132–136.
[38] H.C. Ha, P.M. Woster, J.D. Yager, R.A. Casero Jr., The role of polyamine catabolism
in polyamine analogue-induced programmed cell death, Proc. Natl. Acad. Sci. U. S. A.
94 (1997) 11557–11562.
[39] I.M. Araujo, B.P. Carreira, C.M. Carvalho, A.P. Carvalho, Calpains and delayed calci-
um deregulation in excitotoxicity, Neurochem. Res. 35 (2010) 1966–1969.
[40] K. Szydlowska, M. Tymianski, Calcium, ischemia and excitotoxicity, Cell Calcium
47 (2010) 122–129.
[41] M.J. O'Hare, N. Kushwaha, Y. Zhang, H. Aleyasin, S.M. Callaghan, R.S. Slack, P.R.
Albert, I. Vincent, D.S. Park, Differential roles of nuclear and cytoplasmic cyclin-
dependent kinase 5 in apoptotic and excitotoxic neuronal death, J. Neurosci. 25
(2005) 8954–8966.
[42] A. Rami, D. Ferger, J. Krieglstein, Blockade of calpain proteolytic activity rescues
neurons from glutamate excitotoxicity, Neurosci. Res. 27 (1997) 93–97.
[43] L. Meijer, A. Borgne, O. Mulner, J.P. Chong, J.J. Blow, N. Inagaki, M. Inagaki, J.G.
Delcros, J.P. Moulinoux, Biochemical and cellular effects of roscovitine, a potent
and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5,
Eur. J. Biochem. 243 (1997) 527–536.
[44] J.C. Augustinack, A. Schneider, E.M. Mandelkow, B.T. Hyman, Speciﬁc tau phosphor-
ylation sites correlate with severity of neuronal cytopathology in Alzheimer's
disease, Acta Neuropathol. 103 (2002) 26–35.
[45] C.P. Emerson, Myogenesis and developmental control genes, Curr. Opin. Cell Biol.
2 (1990) 1065–1075.
[46] J. Rashidian, M.W. Rousseaux, K. Venderova, D. Qu, S.M. Callaghan, M. Phillips, R.J.
Bland, M.J. During, Z. Mao, R.S. Slack, D.S. Park, Essential role of cytoplasmic cdk5
and Prx2 in multiple ischemic injury models, in vivo, J. Neurosci. 29 (2009)
12497–12505.
[47] M. Gomez-Lazaro, M.F. Galindo, R.M. Melero-Fernandez de Mera, F.J. Fernandez-
Gomez, C.G. Concannon, M.F. Segura, J.X. Comella, J.H. Prehn, J. Jordan, Reactive
oxygen species and p38 mitogen-activated protein kinase activate Bax to induce
mitochondrial cytochrome c release and apoptosis in response to malonate,
Mol. Pharmacol. 71 (2007) 736–743.
[48] F.J. Fernandez-Gomez, M.F. Galindo, M. Gomez-Lazaro, V.J. Yuste, J.X. Comella, N.
Aguirre, J. Jordan, Malonate induces cell death via mitochondrial potential col-
lapse and delayed swelling through an ROS-dependent pathway, Br. J. Pharmacol.
144 (2005) 528–537.
[49] L. Yang, S. Sugama, R.P. Mischak, M. Kiaei, N. Bizat, E. Brouillet, T.H. Joh, M.F. Beal,
A novel systemically active caspase inhibitor attenuates the toxicities of MPTP,
malonate, and 3NP in vivo, Neurobiol. Dis. 17 (2004) 250–259.
[50] R.C. Taylor, S.P. Cullen, S.J. Martin, Apoptosis: controlled demolition at the cellular
level, Nat. Rev. Mol. Cell Biol. 9 (2008) 231–241.
[51] S.J. Korsmeyer, M.C. Wei, M. Saito, S. Weiler, K.J. Oh, P.H. Schlesinger,
Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores
that result in the release of cytochrome c, Cell Death Differ. 7 (2000) 1166–1173.
[52] L. Galluzzi, K. Blomgren, G. Kroemer, Mitochondrial membrane permeabilization
in neuronal injury, Nat. Rev. Neurosci. 10 (2009) 481–494.
[53] R. Henshaw, B.G. Jenkins, J.B. Schulz, R.J. Ferrante, N.W. Kowall, B.R. Rosen, M.F.
Beal, Malonate produces striatal lesions by indirect NMDA receptor activation,
Brain Res. 647 (1994) 161–166.
[54] L. Barros-Minones, L. Orejana, B. Goni-Allo, V. Suquia, I. Hervias, N. Aguirre, E.
Puerta, Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates
sildenaﬁl protection against chemical hypoxia caused bymalonate, Br. J. Pharmacol.
(2012).
[55] M. Arundine, M. Tymianski, Molecular mechanisms of glutamate-dependent
neurodegeneration in ischemia and traumatic brain injury, Cell. Mol. Life Sci. 61
(2004) 657–668.
[56] M.M. Fan, L.A. Raymond, N-methyl-D-aspartate (NMDA) receptor function and
excitotoxicity in Huntington's disease, Prog. Neurobiol. 81 (2007) 272–293.
[57] A. Lau, M. Tymianski, Glutamate receptors, neurotoxicity and neurodegeneration,
Pﬂugers Arch. 460 (2010) 525–542.
[58] E.A. Waxman, D.R. Lynch, N-methyl-D-aspartate receptor subtypes: multiple
roles in excitotoxicity and neurological disease, Neuroscientist 11 (2005) 37–49.
[59] J. Takano, M. Tomioka, S. Tsubuki, M. Higuchi, N. Iwata, S. Itohara, M. Maki, T.C.
Saido, Calpain mediates excitotoxic DNA fragmentation via mitochondrial path-
ways in adult brains: evidence from calpastatin mutant mice, J. Biol. Chem. 280
(2005) 16175–16184.[60] J. Jordan, M.F. Galindo, R.J. Miller, Role of calpain- and interleukin-1 beta
converting enzyme-like proteases in the beta-amyloid-induced death of rat
hippocampal neurons in culture, J. Neurochem. 68 (1997) 1612–1621.
[61] R. Nath, M. Davis, A.W. Probert, N.C. Kupina, X. Ren, G.P. Schielke, K.K. Wang,
Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely
injured neuronal cells, Biochem. Biophys. Res. Commun. 274 (2000) 16–21.
[62] H. Patzke, L.H. Tsai, Calpain-mediated cleavage of the cyclin-dependent kinase-5
activator p39 to p29, J. Biol. Chem. 277 (2002) 8054–8060.
[63] S. Hisanaga, R. Endo, Regulation and role of cyclin-dependent kinase activity in
neuronal survival and death, J. Neurochem. 115 (2010) 1309–1321.
[64] J. Wang, S. Liu, Y. Fu, J.H. Wang, Y. Lu, Cdk5 activation induces hippocampal CA1
cell death by directly phosphorylating NMDA receptors, Nat. Neurosci. 6 (2003)
1039–1047.
[65] N. Mitsios, R. Pennucci, J. Krupinski, C. Sanfeliu, J. Gaffney, P. Kumar, S. Kumar, O.
Juan-Babot, M. Slevin, Expression of cyclin-dependent kinase 5 mRNA and protein
in the human brain following acute ischemic stroke, Brain Pathol. 17 (2007) 11–23.
[66] B.S. Li, M.K. Sun, L. Zhang, S. Takahashi, W. Ma, L. Vinade, A.B. Kulkarni, R.O. Brady,
H.C. Pant, Regulation of NMDA receptors by cyclin-dependent kinase-5, Proc.
Natl. Acad. Sci. U. S. A. 98 (2001) 12742–12747.
[67] J. Kanungo, Y.L. Zheng, N.D. Amin, H.C. Pant, Targeting Cdk5 activity in neuronal
degeneration and regeneration, Cell. Mol. Neurobiol. 29 (2009) 1073–1080.
[68] A. Camins, E. Verdaguer, J. Folch, A.M. Canudas, M. Pallas, The role of CDK5/P25
formation/inhibition in neurodegeneration, Drug News Perspect. 19 (2006)
453–460.
[69] Y. Wen, S.H. Yang, R. Liu, E.J. Perez, A.M. Brun-Zinkernagel, P. Koulen, J.W.
Simpkins, Cdk5 is involved in NFT-like tauopathy induced by transient cerebral
ischemia in female rats, Biochim. Biophys. Acta 1772 (2007) 473–483.
[70] M. Morioka, T. Kawano, S. Yano, Y. Kai, H. Tsuiki, Y. Yoshinaga, J. Matsumoto, T.
Maeda, J. Hamada, H. Yamamoto, K. Fukunaga, J. Kuratsu, Hyperphosphorylation
at serine 199/202 of tau factor in the gerbil hippocampus after transient forebrain
ischemia, Biochem. Biophys. Res. Commun. 347 (2006) 273–278.
[71] K.A. Heidenreich, D.A. Linseman, Myocyte enhancer factor-2 transcription factors
in neuronal differentiation and survival, Mol. Neurobiol. 29 (2004) 155–166.
[72] X. Tang, X. Wang, X. Gong, M. Tong, D. Park, Z. Xia, Z. Mao, Cyclin-dependent
kinase 5 mediates neurotoxin-induced degradation of the transcription factor
myocyte enhancer factor 2, J. Neurosci. 25 (2005) 4823–4834.
[73] X. Gong, X. Tang, M. Wiedmann, X. Wang, J. Peng, D. Zheng, L.A. Blair, J. Marshall,
Z. Mao, Cdk5-mediated inhibition of the protective effects of transcription factor
MEF2 in neurotoxicity-induced apoptosis, Neuron 38 (2003) 33–46.
[74] E. Verdaguer, D. Alvira, A. Jimenez, V. Rimbau, A. Camins, M. Pallas, Inhibition of
the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain
inhibitors in cerebellar neurons, Br. J. Pharmacol. 145 (2005) 1103–1111.
[75] S. Okamoto, Z. Li, C. Ju, M.N. Scholzke, E. Mathews, J. Cui, G.S. Salvesen, E.
Bossy-Wetzel, S.A. Lipton, Dominant-interfering forms of MEF2 generated by
caspase cleavage contribute to NMDA-induced neuronal apoptosis, Proc. Natl.
Acad. Sci. U. S. A. 99 (2002) 3974–3979.
[76] S. Gregoire, A.M. Tremblay, L. Xiao, Q. Yang, K. Ma, J. Nie, Z. Mao, Z. Wu, V. Giguere,
X.J. Yang, Control of MEF2 transcriptional activity by coordinated phosphoryla-
tion and sumoylation, J. Biol. Chem. 281 (2006) 4423–4433.
[77] D.M. Cox, M. Du, M. Marback, E.C. Yang, J. Chan, K.W. Siu, J.C. McDermott, Phos-
phorylation motifs regulating the stability and function of myocyte enhancer
factor 2A, J. Biol. Chem. 278 (2003) 15297–15303.
[78] Y. Yin, H. She, W. Li, Q. Yang, S. Guo, Z. Mao, Modulation of neuronal survival
factor MEF2 by kinases in Parkinson's disease, Front. Physiol. 3 (2012) 171.
[79] J.D. Molkentin, L. Li, E.N. Olson, Phosphorylation of the MADS-Box transcription
factor MEF2C enhances its DNA binding activity, J. Biol. Chem. 271 (1996)
17199–17204.
[80] B. Levine, S. Sinha, G. Kroemer, Bcl-2 family members: dual regulators of apopto-
sis and autophagy, Autophagy 4 (2008) 600–606.
[81] M.E. Gibson, B.H. Han, J. Choi, C.M. Knudson, S.J. Korsmeyer, M. Parsadanian,
D.M. Holtzman, BAX contributes to apoptotic-like death following neonatal
hypoxia–ischemia: evidence for distinct apoptosis pathways, Mol. Med. 7 (2001)
644–655.
[82] S. Toulmond, K. Tang, Y. Bureau, H. Ashdown, S. Degen, R. O'Donnell, J. Tam, Y.
Han, J. Colucci, A. Giroux, Y. Zhu, M. Boucher, B. Pikounis, S. Xanthoudakis, S.
Roy, M. Rigby, R. Zamboni, G.S. Robertson, G.Y. Ng, D.W. Nicholson, J.P.
Fluckiger, Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in
the rat malonate model of Huntington's disease, Br. J. Pharmacol. 141 (2004)
689–697.
[83] O.A. Andreassen, R.J. Ferrante, D.B. Hughes, P. Klivenyi, A. Dedeoglu, V.O. Ona,
R.M. Friedlander, M.F. Beal, Malonate and 3-nitropropionic acid neurotoxicity
are reduced in transgenic mice expressing a caspase-1 dominant-negative mu-
tant, J. Neurochem. 75 (2) (Aug 2000) 847–852.
[84] T. Sasaki, K. Kitagawa, Y. Yagita, S. Sugiura, E. Omura-Matsuoka, S. Tanaka, K.
Matsushita, H. Okano, Y. Tsujimoto, M. Hori, Bcl2 enhances survival of newborn
neurons in the normal and ischemic hippocampus, J. Neurosci. Res. 84 (2006)
1187–1196.
[85] S. Pugazhenthi, A. Nesterova, C. Sable, K.A. Heidenreich, L.M. Boxer, L.E. Heasley, J.E.
Reusch, Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response
element-binding protein, J. Biol. Chem. 275 (2000) 10761–10766.
[86] A. Das, L. Xi, R.C. Kukreja, Protein kinase G-dependent cardioprotective mecha-
nism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and
GSK3beta, J. Biol. Chem. 283 (2008) 29572–29585.
[87] J.B. Schulz, R.T. Matthews, B.G. Jenkins, P. Brar, M.F. Beal, Improved therapeutic win-
dow for treatment of histotoxic hypoxia with a free radical spin trap, J. Cereb. Blood
Flow Metab. 15 (1995) 948–952.
